Zhijie Wang

List of Publications by Citations

71 papers	2,182 citations	24 h-index	46 g-index
88 ext. papers	3,066 ext. citations	6 avg, IF	4.77 L-index

#	Paper	IF	Citations
71	Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 21083-8	11.5	344
70	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. *JAMA Oncology*, **2019**, 5, 696-702	13.4	237
69	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, **2012**, 30, 3077-83	2.2	154
68	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2020**, 6, 375-384	13.4	110
67	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. *PLoS ONE*, **2014**, 9, e110780	3.7	109
66	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. *Journal of Thoracic Oncology*, **2020**, 15, 816-826	8.9	106
65	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. *Cancer Research*, **2018**, 78, 6486-6496	10.1	104
64	Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. *Lancet Respiratory Medicine,the*, **2018**, 6, 681-690	35.1	103
63	Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. *PLoS ONE*, **2013**, 8, e54170	3.7	76
62	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2020**, 8, 146-154	12.5	72
61	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. *Oncotarget*, **2016**, 7, 20810-24	3.3	63
60	Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. *Cancer Research*, **2019**, 79, 7-20	10.1	63
59	Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. *JAMA Oncology*, **2020**, 6, 631-632	13.4	59
58	Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 709-717	13.4	45
57	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. *Oncology*, **2012**, 83, 248-56	3.6	36
56	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). *Journal of Thoracic Oncology*, **2017**, 12, 1766-1778	8.9	35
55	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. *Thoracic Cancer*, **2012**, 3, 334-340	3.2	35

54	Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells. *Clinical Cancer Research*, **2019**, 25, 5049-5060	12.9	31
53	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1376-1387	8.9	29
52	Hypoxia-inducible factor-1 and nuclear factor-B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. *Cancer Science*, **2019**, 110, 1665-1675	6.9	28
51	Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic Profiling. *Clinical Cancer Research*, **2018**, 24, 2100-2109	12.9	28
50	Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. *Journal of Thoracic Oncology*, **2020**, 15, 556-567	8.9	27
49	Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9990-5	11.5	24
48	The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 1209-1219	8.8	23
47	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer **2019**, 7, 198		19
46	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial. *JAMA Network Open*, **2020**, 3, e2013770	10.4	15
45	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. *Lancet Oncology, The*, **2021**, 22, 1265-1274	21.7	15
44	Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer. *Cancer Letters*, **2019**, 440-441, 180-188	9.9	12
43	Analysis of mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. *Oncology Letters*, **2017**, 13, 2425-2431	2.6	11
42	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. *Journal of Thoracic Oncology*, **2021**, 16, 1099-1117	8.9	11
41	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. *Thoracic Cancer*, **2021**, 12, 66-78	3.2	10
40	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. *Oncotarget*, **2016**, 7, 35132-43	3.3	9
39	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. *Lung Cancer*, **2020**, 147, 259-268	5.9	9
38	High-fidelity of non-small cell lung cancer xenograft models derived from bronchoscopy-guided biopsies. *Thoracic Cancer*, **2016**, 7, 100-10	3.2	9
37	Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. *Npj Precision Oncology*, **2020**, 4, 32	9.8	8

36	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 1166-1173	3.2	7
35	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. *Journal of Thoracic Oncology*, **2020**, 15, 1857-1870	8.9	7
34	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. *BMC Medicine*, **2020**, 18, 232	11.4	7
33	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. *Nature Communications*, **2020**, 11, 4878	17.4	6
32	TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211038477	5.4	6
31	Systematic investigations of COVID-19 in 283 cancer patients		5
30	A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based p.T790M in non-small-cell lung cancer patients. *Translational Lung Cancer Research*, **2021**, 10, 3888-3901	4.4	3
29	Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. *Thoracic Cancer*, **2020**, 11, 3501-3509	3.2	3
28	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. *Frontiers in Immunology*, **2020**, 11, 527750	8.4	3
27	Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors. *Cancer Management and Research*, **2020**, 12, 7151-7164	3.6	3
26	Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 805-813	3.2	3
25	MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.. *Molecular Diagnosis and Therapy*, **2022**, 26, 203	4.5	3
24	Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. *Thoracic Cancer*, **2020**, 11, 1149-1159	3.2	2
23	The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. *Journal of Cancer*, **2020**, 11, 3106-3113	4.5	2
22	Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer. *Thoracic Cancer*, **2020**, 11, 713-722	3.2	2
21	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.. *Journal of Clinical Oncology*, **2021**, 39, 8522-8522	2.2	2
20	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. *Science Advances*, **2021**, 7,	14.3	2
19	International consensus on severe lung cancer-the first edition. *Translational Lung Cancer Research*, **2021**, 10, 2633-2666	4.4	2

18	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2016**, 28, 12-8	3.8	1
17	Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays.. *Translational Lung Cancer Research*, **2021**, 10, 4336-4352	4.4	1
16	Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.. *Journal of Clinical Oncology*, **2018**, 36, 3024-3024	2.2	1
15	Evaluation of radical surgical treatment in the management of 58 locally advanced rectal neuroendocrine neoplasms, one multicenter retrospective study. *European Journal of Surgical Oncology*, **2021**,	3.6	1
14	Bevacizumab combined with pemetrexed successfully treated lung adenocarcinoma complicated with pulmonary tumor thrombotic microangiopathy: a case report and literature review. *Annals of Palliative Medicine*, **2021**, 10, 767-777	1.7	1
13	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. *Thoracic Cancer*, **2018**, 9, 1716-1724	3.2	1
12	Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer. *JAMA Oncology*, **2020**, 6, 932	13.4	0
11	Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. *Journal of the National Cancer Center*, **2021**, 1, 153-153		0
10	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. *BMC Medicine*, **2021**, 19, 239	11.4	0
9	Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.. *Frontiers in Endocrinology*, **2021**, 12, 801741	5.7	0
8	Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer-Reply. *JAMA Oncology*, **2020**, 6, 1116-1117	13.4	
7	In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy. *Journal of Thoracic Oncology*, **2020**, 15, e72-e73	8.9	
6	Associations between mutations of DNA damage response and prognosis in microsatellite instability prevalent tumors.. *Journal of Clinical Oncology*, **2018**, 36, e24257-e24257	2.2	
5	The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy.. *Journal of Clinical Oncology*, **2018**, 36, e15007-e15007	2.2	
4	Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).. *Journal of Clinical Oncology*, **2018**, 36, e21184-e21184	2.2	
3	Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.. *Journal of Clinical Oncology*, **2018**, 36, 12034-12034	2.2	
2	Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2020**, 38, e13528-e13528	2.2	
1	Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.. *Journal of Clinical Oncology*, **2021**, 39, e21002-e21002	2.2	